House Appropriators' Report Tracks With FDA Concern About CBD Supplements

House Appropriators expect FDA to assert commitment to identifying lawful regulatory pathways for CBD food and supplements if those pathways are consistent with protection of public health. Committee also expresses concern over proliferation of CBD supplements and foods in violation of FDA regulations.

FDA words adn building icon

The US House Appropriations Committee's report with its fiscal year 2020 spending bill for the Food and Drug Administration states concern over the proliferation of foods and dietary supplements containing cannabidiols in violation of federal regulations.

The FY 2020 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies” appropriation bill, passed along party lines...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

US Tax Code Already Spells Using HSA/FSAs For Dietary Supplement Purchases, NPA Tells IRS

 

Internal Revenue Code should include within its definition of “medical care” spending the consumers' purchases of supplement products based on labeling of FDA-approved health and structure/function claims, NPA CEO Daniel Fabricant says.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Utah Delegation’s Support For Supplement Industry Key For Caucus Restart In Congress

 

Dietary Supplement Caucus e-launched the 119th Congress with Utah Republican House member Mike Kennedy and Texas Democrat member Marc Veasey as co-chairs and with a total of nine senators and 20 House members spanning both parties.

Price To Resolve US Hemp Dilemma Too High In House Appropriators’ FY 2026 FDA Spending Bill

 

Provisions in bill approved by Agriculture, Rural Development, FDA and Related Agencies Subcommittee aren’t likely to pass largely because they set a price too high for delta-8 THC and other ingredients to meet the definition of hemp as a de-scheduled substance.

More from Policy & Regulation

FDA RIF Delays Response On NPA NMN Petition

 

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.